Arrowhead Research Corp (NASDAQ:ARWR)

CAPS Rating: 3 out of 5

A development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy.

Results 1 - 20 of 35 : 1 2 Next »

Recs

0
Member Avatar AsianMatter (52.80) Submitted: 4/12/2014 11:38:47 AM : Outperform Start Price: $13.76 ARWR Score: -11.70

get in

Recs

1
Member Avatar PrototypeZ (23.45) Submitted: 2/19/2014 12:03:26 PM : Outperform Start Price: $21.48 ARWR Score: -43.40

Let's see if the malibu man is right

Recs

0
Member Avatar goodtargets (< 20) Submitted: 1/30/2014 7:09:50 AM : Underperform Start Price: $14.51 ARWR Score: +18.67

Too early, too many hurdles

Recs

1
Member Avatar Liberty4Freedom (< 20) Submitted: 12/23/2013 1:57:32 PM : Outperform Start Price: $10.60 ARWR Score: +14.77

An announcement is coming after January 2014.

Recs

1
Member Avatar NoDoughBro (70.19) Submitted: 7/31/2013 8:46:57 PM : Outperform Start Price: $3.82 ARWR Score: +214.85

Watch and learn.

Recs

4
Member Avatar zzlangerhans (99.74) Submitted: 4/23/2013 11:53:25 PM : Outperform Start Price: $1.74 ARWR Score: +592.32

Arrowhead Research has labored on various endeavors in relative obscurity for quite a number of years. I've had difficulty uncovering much details regarding their operations before 2012, but it seems as though they acted as an umbrella company for various subsidiaries with quite diverse operations across the biotech and engineering spaces. Recently they've generated a little buzz by acquiring homing peptide technology through the acquisition of privately-held Alvos, which they intend to conjugate to cytotoxic compounds or siRNA's for the treatment of obesity, cancer, and hepatitis.

All of this sounds like a solid platform for an investment, except that the five year chart is rather grim in appearance with a single remarkable and short-lived spike in early 2010. There was also a 10:1 reverse split in late 2011. Clearly, not all is well at Arrowhead but again details are hard to come by.

At a market cap of 30M, Arrowhead seems to have quite a number of pipeline assets with at least two compounds in early clinical trials and an IND for a third planned for this quarter, as well as active collaborations with Shire and Merck. However, the company is very low on cash and has historically not been shy to access the capital markets for replenishment of their runway.

Normally, I might set Arrowhead aside pending further clarity on their solvency and ability to progress drug candidates through clinical trials, but I have been instructed to buy 3000 shares at 1.75 for the Portefeuille collaboration. This green thumb therefore serves to support the real investment for the collaboration and provide a reference point for future trades.

Recs

1
Member Avatar import2udirect (90.24) Submitted: 1/29/2012 6:54:14 AM : Outperform Start Price: $3.75 ARWR Score: +192.73

nano robotic surgery is the future and will replace high risk surgeries in the future that have a difficult entry point or are near main arteries or the heart

Recs

1
Member Avatar Jxson (< 20) Submitted: 12/3/2010 11:06:30 AM : Outperform Start Price: $9.17 ARWR Score: -16.94

This stock has multiple high potential new technologies in early developement. If they hit on any one of them, it would be a blockbuster. They also provide an attractive takeover target in whole or part.

Recs

0
Member Avatar franktejon (< 20) Submitted: 7/6/2010 9:37:40 AM : Outperform Start Price: $10.30 ARWR Score: -59.50

strong buy

Recs

1
Member Avatar bodie17 (52.23) Submitted: 7/2/2010 5:35:52 PM : Outperform Start Price: $11.80 ARWR Score: -65.27

New RNA thing.

Recs

1
Member Avatar Fixitguy (< 20) Submitted: 5/1/2008 12:48:25 PM : Outperform Start Price: $26.80 ARWR Score: -91.44

They are doing research on carbon nanotubes, siRNA, even fullerenes from a Nobel Prize laureate. ARWR is like investing in a venture capital firm involved with leading edge tech and biotech.

Recently they spun off a company called Ensyse Biosciences, which is researching ways to use carbo nanotubes to shrink cancer tumor cells. One of the researchers, Dr. Steven Curley of the M. D. Anderson Cancer Center, is being funded by them. He was featured on a 60 Minutes segment recently.

The stock is volatile, and very small cap. But if the research projects they invest in take off, so will the share price.

Recs

0
Member Avatar drod0886 (72.81) Submitted: 3/27/2008 1:01:31 PM : Outperform Start Price: $32.99 ARWR Score: -106.56

carbon nanotubes baby!

Recs

0
Member Avatar rlandrem (< 20) Submitted: 1/25/2008 6:32:59 PM : Outperform Start Price: $28.90 ARWR Score: -99.65

Gamble on!

Recs

0
Member Avatar abacusdude (97.81) Submitted: 12/28/2007 10:44:50 AM : Outperform Start Price: $38.40 ARWR Score: -98.99

Only $0.70 above their 52 wk. low. Good time to buy, and expected to be at $9 in a year.

Recs

0
Member Avatar RCHTARA (< 20) Submitted: 12/6/2007 7:56:50 PM : Outperform Start Price: $40.60 ARWR Score: -98.27

en, this tech. should increase the intrnic value

Recs

0
Member Avatar buzzback (21.65) Submitted: 11/15/2007 11:08:31 PM : Outperform Start Price: $44.80 ARWR Score: -105.63

ARWR has the most Nanotech patents. 3 subs, one of those being biotech. If oneof these hit or any of their other potential products, ARWR will blow the S7P out of the water.

Recs

0
Member Avatar Jchoiboy (< 20) Submitted: 11/5/2007 11:06:25 PM : Outperform Start Price: $36.90 ARWR Score: -95.68

Go Beta!

Recs

0
Member Avatar pkihei (< 20) Submitted: 11/4/2007 12:00:16 PM : Outperform Start Price: $54.70 ARWR Score: -112.28

No pitch just i personally own this stock and i am buying more not selling at these levels $3.92 11/02/2007 sometimes you just have to break the rules i don't know if this will prove to be a profitable move or not but i am adding to my position as i do think that nano -tech will be a very profitable area in the future

Recs

0
Member Avatar allsporty (73.52) Submitted: 8/24/2007 3:45:45 PM : Outperform Start Price: $50.00 ARWR Score: -107.47

Government spending on carbon nanotubes is just beginning. Once the government is involved private equity will soon follow.

Recs

0
Member Avatar GruenHouse (< 20) Submitted: 7/24/2007 4:59:32 AM : Outperform Start Price: $44.60 ARWR Score: -100.18

When carbon nanotubes go.. so will this..

Results 1 - 20 of 35 : 1 2 Next »

Featured Broker Partners


Advertisement